Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up

Table 1

Baseline demographics of patients and eyes.

Total number of patients/eyes	180
Age
Mean (years) ± SD	75 ± 9
Range (years)	51–96
Sex, n (%)
Male	75 (41.7%)
Female	105 (58.3%)
Laterality of disease at first visit, n (%)
Unilateral	146 (81.1%)
Bilateral	34 (18.9%)
Past ocular history, n (%)
Pseudophakic	92 (51.1%)
Glaucoma	15 (8.3%)
Pars plana vitrectomy	1 (0.6%)
Past nAMD treatment, n (%)
None	121 (67.2%)
Anti-VEGF	58 (32.2%)
Intravitreal corticosteroid	1 (0.6%)
Argon laser for extrafoveal CNV	3 (1.7%)
Photodynamic therapy	0 (0.0%)

Categories not mutually exclusive, except for “Past nAMD treatment: None”.